Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Alica K Beutel"'
Autor:
Frank Arnold, Pallavi U Mahaddalkar, Johann M. Kraus, Xiaowei Zhong, Wendy Bergmann, Dharini Srinivasan, Johann Gout, Elodie Roger, Alica K. Beutel, Eugen Zizer, Umesh Tharehalli, Nora Daiss, Ronan Russell, Lukas Perkhofer, Rupert Oellinger, Qiong Lin, Ninel Azoitei, Frank‐Ulrich Weiss, Markus M. Lerch, Stefan Liebau, Sarah‐Fee Katz, André Lechel, Roland Rad, Thomas Seufferlein, Hans A. Kestler, Michael Ott, Amar Deep Sharma, Patrick C. Hermann, Alexander Kleger
Publikováno v:
Advanced Science, Vol 8, Iss 14, Pp n/a-n/a (2021)
Abstract Somatic cell reprogramming and tissue repair share relevant factors and molecular programs. Here, Dickkopf‐3 (DKK3) is identified as novel factor for organ regeneration using combined transcription‐factor‐induced reprogramming and RNA
Externí odkaz:
https://doaj.org/article/9550ae6160b44a838337eb3885f4db0c
Publikováno v:
American Journal of Physiology-Cell Physiology. 324:C540-C552
Pancreatic ductal adenocarcinoma (PDA) has become one of the leading causes of cancer-related deaths across the world. A lack of durable responses to standard-of-care chemotherapies renders its treatment particularly challenging and largely contribut
Autor:
Christopher J. Halbrook, Galloway Thurston, Seth Boyer, Cecily Anaraki, Jennifer A. Jiménez, Amy McCarthy, Nina G. Steele, Samuel A. Kerk, Hanna S. Hong, Lin Lin, Fiona V. Law, Catherine Felton, Lorenzo Scipioni, Peter Sajjakulnukit, Anthony Andren, Alica K. Beutel, Rima Singh, Barbara S. Nelson, Fran Van Den Bergh, Abigail S. Krall, Peter J. Mullen, Li Zhang, Sandeep Batra, Jennifer P. Morton, Ben Z. Stanger, Heather R. Christofk, Michelle A. Digman, Daniel A. Beard, Andrea Viale, Ji Zhang, Howard C. Crawford, Marina Pasca di Magliano, Claus Jorgensen, Costas A. Lyssiotis
Publikováno v:
Nature cancer, vol 3, iss 11
Nature Cancer
Nature Cancer
The pancreatic tumor microenvironment drives deregulated nutrient availability. Accordingly, pancreatic cancer cells require metabolic adaptations to survive and proliferate. Pancreatic cancer subtypes have been characterized by transcriptional and f
Autor:
Lukas Perkhofer, Talia Golan, Pieter-Jan Cuyle, Tamara Matysiak-Budnik, Jean-Luc Van Laethem, Teresa Macarulla, Estelle Cauchin, Alexander Kleger, Alica K. Beutel, Johann Gout, Albrecht Stenzinger, Eric Van Cutsem, Joaquim Bellmunt, Pascal Hammel, Eileen M. O’Reilly, Thomas Seufferlein
Publikováno v:
Cancers, Vol 13, Iss 17, p 4259 (2021)
Impaired DNA damage repair (DDR) is increasingly recognised as a hallmark in pancreatic ductal adenocarcinoma (PDAC). It is estimated that around 14% of human PDACs harbour mutations in genes involved in DDR, including, amongst others, BRCA1/2, PALB2
Externí odkaz:
https://doaj.org/article/22a0450c09e14674ac6c1e5c5e4597ea
Autor:
Alica K. Beutel, Lena Schütte, Jeanette Scheible, Elodie Roger, Martin Müller, Lukas Perkhofer, Annika M. T. U. Kestler, Johann M. Kraus, Hans A. Kestler, Thomas F. E. Barth, Johannes Lemke, Marko Kornmann, Thomas J. Ettrich, Johann Gout, Thomas Seufferlein, Alexander Kleger
Publikováno v:
Cancers, Vol 13, Iss 11, p 2539 (2021)
Real-time isolation, propagation, and pharmacotyping of patient-derived pancreatic cancer organoids (PDOs) may enable treatment response prediction and personalization of pancreatic cancer (PC) therapy. In our methodology, PDOs are isolated from 54 p
Externí odkaz:
https://doaj.org/article/22db37dd04b44b14a8f82a0d80cbc195
Autor:
Elodie Roger, Johann Gout, Frank Arnold, Alica K. Beutel, Martin Müller, Alireza Abaei, Thomas F. E. Barth, Volker Rasche, Thomas Seufferlein, Lukas Perkhofer, Alexander Kleger
Publikováno v:
Cells, Vol 9, Iss 9, p 2110 (2020)
Personalized medicine in treating pancreatic ductal adenocarcinoma (PDAC) is still in its infancy, albeit PDAC-related deaths are projected to rise over the next decade. Only recently, maintenance therapy with the PARP inhibitor olaparib showed impro
Externí odkaz:
https://doaj.org/article/800b1111887b47ce94fb37d8b8b3dddc
Autor:
Eric Van Cutsem, Teresa Macarulla, Pascal Hammel, Albrecht Stenzinger, Thomas Seufferlein, Jean-Luc Van Laethem, Eileen M. O'Reilly, Alexander Kleger, Pieter-Jan Cuyle, Joaquim Bellmunt, Estelle Cauchin, Lukas Perkhofer, Tamara Matysiak-Budnik, Johann Gout, Alica K Beutel, Talia Golan
Publikováno v:
Cancers (Basel), 13 (17
Cancers, Vol 13, Iss 4259, p 4259 (2021)
Scientia
Cancers
Cancers, Vol 13, Iss 4259, p 4259 (2021)
Scientia
Cancers
Impaired DNA damage repair (DDR) is increasingly recognised as a hallmark in pancreatic ductal adenocarcinoma (PDAC). It is estimated that around 14% of human PDACs harbour mutations in genes involved in DDR, including, amongst others, BRCA1/2, PALB2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c064448577161c2189c34b51c136bfa
Publikováno v:
Im Fokus Onkologie. 22:14-18
Eine operative Resektion in kurativer Intention kommt nur bei weniger als 20 % der Patienten mit einem Pankreaskarzinom infrage. Allerdings ermoglichen neue Standardtherapien in der palliativen Erstlinienbehandlung eine signifikante Verbesserung des
Autor:
Lukas Perkhofer, Johannes R. Lemke, Marko Kornmann, Tfe Barth, J. Kraus, Amtu Kestler, Thomas Seufferlein, Hans A. Kestler, Alexander Kleger, Elodie Roger, Thomas J. Ettrich, Jeanette Scheible, L Schütte, Martin Müller, Alica K Beutel, Johann Gout
Publikováno v:
Cancers
Cancers, Vol 13, Iss 2539, p 2539 (2021)
Volume 13
Issue 11
Cancers, Vol 13, Iss 2539, p 2539 (2021)
Volume 13
Issue 11
Real-time isolation, propagation, and pharmacotyping of patient-derived pancreatic cancer organoids (PDOs) may enable treatment response prediction and personalization of pancreatic cancer (PC) therapy. In our methodology, PDOs are isolated from 54 p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::040d92b47c9fe3b37d38c24aafa3f757
Autor:
Thomas F. E. Barth, Lukas Perkhofer, Volker Rasche, Alireza Abaei, Frank Arnold, Martin Müller, Elodie Roger, Alica K Beutel, Alexander Kleger, Thomas Seufferlein, Johann Gout
Publikováno v:
Cells
Volume 9
Issue 9
Cells, Vol 9, Iss 2110, p 2110 (2020)
Volume 9
Issue 9
Cells, Vol 9, Iss 2110, p 2110 (2020)
Personalized medicine in treating pancreatic ductal adenocarcinoma (PDAC) is still in its infancy, albeit PDAC-related deaths are projected to rise over the next decade. Only recently, maintenance therapy with the PARP inhibitor olaparib showed impro